摘要
目的:评价芳香化酶抑制剂(aromatase inhibitors,AI)的安全性。方法:对国内近10年公开发表的有关应用AI出现的不良反应(adverse drug events,ADR)进行文献计量学研究。结果:到目前为止AI不良反应较少,值得临床推广使用,但长期服用对心血管和骨丢失的影响有待于进一步观察、研究。第一代AI表现出最普遍的不良反应,第二、三代AI可能对骨和心血管有相对更大的风险。结论:临床应用应警惕AI在心血管和骨组织方面的影响,同时加强AI在长期使用时的监测,促进临床安全合理用药。
OBJECTIVE To Review the safety of aromatase inhibitors （AI）. METHODS Articles about the ADRs of AI for the treatment of breast cancer in the latest 10 years in China were collected for metrology analysis. RESULTS Few ADRs of AI were detected, but the impact of heart-blood system and bone tissue for longtime use was needed. The first generation AI caused common ADRs, while the second and third generation resulted in risks in heart-blood system and bone tissue. CONCLUSION ADR should be monitored for clinic use of AI on heart-blood system and bone tissue,especially for the long-term use.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2009年第8期654-657,共4页
Chinese Journal of Hospital Pharmacy
关键词
芳香化酶抑制剂
乳腺癌
不良反应
aromatase inhibitors（AI）
breast cancer
adverse drug events（ADRs）
